| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06623409 | Safety and Immunogenicity of V540B in Healthy Adults (V540B-002). | PHASE1 | ACTIVE NOT_RECRUITING | 72 | — | — | Nov 12, 2024 | Nov 20, 2026 | Aug 3, 2025 | 5 | United States |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Solicited systemic AEs include headache, fatigue, nausea, dizziness, muscle aches, joint pain.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
An unsolicited AE is an AE that was not solicited using a vaccine report card (VRC) and that is communicated by a participant (or their legally acceptable representative, if applicable). Unsolicited AEs include serious and nonserious AEs.
Serious adverse events (SAEs) include adverse events that result in any of the following outcomes: death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect.
AEs in which medical attention is received during an unscheduled, non-routine outpatient visit, such as an emergency department visit, office visit, or an urgent care visit with any medical personnel for any reason. Routine visits are not considered medically-attended adverse events (MAAEs). Examples of routine visits include physical examination, wellness visits, or vaccinations.
Events of clinical interest (ECIs) are defined as an overdose of Sponsor's product, drug-induced liver injury events, or potential immune-mediated diseases (pIMDs).
| Arm | Type | Description |
|---|---|---|
| GARDASIL®9 (G9) | ACTIVE_COMPARATOR | Participants will receive vaccinations with G9. |
| V540B | EXPERIMENTAL | Participants will receive vaccinations with V540B. |
| Name | Type | Description |
|---|---|---|
| GARDASIL®9 (G9) | BIOLOGICAL | Suspension administered via intramuscular (IM) injection |
| V540B | BIOLOGICAL | Experimental vaccine and adjuvant administered via IM injection |
Inclusion Criteria: The key inclusion criteria include but are not limited to the following: * Is in good health based on medical history, physical examination, vital sign (VS) measurements and electrocardiograms (ECGs) performed before randomization. Exclusion Criteria: The key exclusion criter...